- Home
- GROV vs MIRA Comparison
GROV vs MIRA Comparison
Compare GROV & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GROV | MIRA |
|---|---|---|
| Founded | 2016 | 2020 |
| Country | United States | United States |
| Employees | 295 | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.8M | 43.7M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | GROV | MIRA |
|---|---|---|
| Price | $1.13 | $1.03 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.60 | N/A |
| AVG Volume (30 Days) | 57.3K | ★ 127.7K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.81 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.03 | $0.90 |
| 52 Week High | $1.60 | $2.45 |
Technical Indicators
Market Signals| Indicator | GROV | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 38.32 | 46.22 |
| Support Level | $1.06 | $0.99 |
| Resistance Level | $1.58 | $1.24 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 22.58 | 24.14 |
Price Performance
Historical ComparisonAbout GROV Grove Collaborative Holdings Inc.
Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.